Kamada Ltd. (KMDA)
NASDAQ: KMDA · IEX Real-Time Price · USD
5.72
-0.17 (-2.89%)
At close: Dec 8, 2023, 4:00 PM
5.75
+0.03 (0.52%)
After-hours: Dec 8, 2023, 7:18 PM EST
Kamada Revenue
Kamada had revenue of $151.53M in the twelve months ending September 30, 2023, with 31.34% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $37.93M with 17.75% year-over-year growth. In the year 2022, Kamada had annual revenue of $129.34M with 24.79% growth.
Revenue (ttm)
$151.53M
Revenue Growth
+31.34%
P/S Ratio
2.17
Revenue / Employee
$398,753
Employees
380
Market Cap
328.75M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 129.34M | 25.70M | 24.79% |
Dec 31, 2021 | 103.64M | -29.60M | -22.22% |
Dec 31, 2020 | 133.25M | 6.06M | 4.76% |
Dec 31, 2019 | 127.19M | 12.72M | 11.11% |
Dec 31, 2018 | 114.47M | 11.64M | 11.32% |
Dec 31, 2017 | 102.83M | 25.33M | 32.69% |
Dec 31, 2016 | 77.49M | 7.59M | 10.85% |
Dec 31, 2015 | 69.91M | -1.16M | -1.63% |
Dec 31, 2014 | 71.07M | 442.00K | 0.63% |
Dec 31, 2013 | 70.62M | -2.05M | -2.82% |
Dec 31, 2012 | 72.68M | 13.19M | 22.18% |
Dec 31, 2011 | 59.48M | 25.01M | 72.53% |
Dec 31, 2010 | 34.48M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tactile Systems Technology | 270.67M |
Sharecare | 239.56M |
Anika Therapeutics | 163.31M |
AxoGen | 152.25M |
LifeMD | 135.81M |
bluebird bio | 21.73M |
Senseonics Holdings | 19.93M |
TScan Therapeutics | 16.93M |
KMDA News
- 1 day ago - KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB® - PRNewsWire
- 2 days ago - Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years - GlobeNewsWire
- 25 days ago - Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance - GlobeNewsWire
- 4 weeks ago - Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023 - GlobeNewsWire
- 2 months ago - Kamada Provides Corporate Update on its Israel Operations - GlobeNewsWire
- 2 months ago - These Israeli pharmaceutical stocks are down in the wake of Hamas attack - Market Watch
- 3 months ago - Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds - GlobeNewsWire
- 4 months ago - Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance - GlobeNewsWire